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Abstract
Background: There is current interest in understanding the molecular mechanisms of tumor-induced bone pain.
Accumulated evidence shows that endogenous formaldehyde concentrations are elevated in the blood or urine of patients
with breast, prostate or bladder cancer. These cancers are frequently associated with cancer pain especially after bone
metastasis. It is well known that transient receptor potential vanilloid receptor 1 (TRPV1) participates in cancer pain. The
present study aims to demonstrate that the tumor tissue-derived endogenous formaldehyde induces bone cancer pain via
TRPV1 activation under tumor acidic environment.
Methodology/Principal Findings: Endogenous formaldehyde concentration increased significantly in the cultured breast
cancer cell lines in vitro, in the bone marrow of breast MRMT-1 bone cancer pain model in rats and in tissues from breast
cancer and lung cancer patients in vivo. Low concentrations (1,5 mM) of formaldehyde induced pain responses in rat via
TRPV1 and this pain response could be significantly enhanced by pH 6.0 (mimicking the acidic tumor microenvironment).
Formaldehyde at low concentrations (1 mM to 100 mM) induced a concentration-dependent increase of [Ca
2+]i in the
freshly isolated rat dorsal root ganglion neurons and TRPV1-transfected CHO cells. Furthermore, electrophysiological
experiments showed that low concentration formaldehyde-elicited TRPV1 currents could be significantly potentiated by low
pH (6.0). TRPV1 antagonists and formaldehyde scavengers attenuated bone cancer pain responses.
Conclusions/Significance: Our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this
formaldehyde at low concentration induces metastatic bone cancer pain through TRPV1 activation especially under tumor
acidic environment.
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Introduction
Cancer pain is a severe clinical condition, and about 75,90%
of advanced or terminal cancer patients experience chronic pain
related to treatment failure and/or tumor progression or
metastasis. Malignant bone tumors occur in patients with primary
bone cancer, but are far more commonly found to be distant
metastases from other primary cancers, notably breast, lung and
prostate cancers. As such, bone is the most common site of origin
of chronic pain in patients with metastatic lung, breast and
prostate cancers and myeloma [1]. In the development of cancer,
it is suggested that tumor tissues secrete different kinds of factors
including cytokines such as TNF-a and IL-1 [2].
Clinical data have shown that formaldehyde concentration is
elevated (2,8 fold) in the urine of patients with prostate and
bladder cancer [3] and in the expired air from tumor-bearing mice
and breast cancer patients [4]; and these patients frequently suffer
from bone cancer pain [5,6]. Formaldehyde is considered to be a
risk factor of cancer development [7], but for the most part
knowledge about formaldehyde secretion by tumor tissue is
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10234limited. Whether excessive endogenous formaldehyde induces
cancer pain still remains to be determined.
A recent report has indicated that formaldehyde (.0.013 mM)
can elicit currents via transient receptor potential vanilloid
receptor 1 (TRPV1) and this current could be blocked by the
specific TRPV1 antagonist capsazepine in dorsal root ganglion
(DRG) neurons [8]. Furthermore, formaldehyde (.0.02 mM) can
induce Ca
2+ influx via TRPV1 and transient receptor potential
ankyrin 1 (TRPA1) in transfected-CHO cells. TRPA1 is more
sensitive to formaldehyde than TRPV1 [9,10], however, TRPA1 is
sensitive to an intracellular alkalization, not an acidic microenvi-
ronment (pH,6.0) [11]. It is well known that tumor tissues
typically exist in an acidic microenvironment in the range of
pH 4,5 [12]. TRPV1 is a cation channel activated by capsaicin,
noxious heat, low pH (pH,5.5) and endogenous vanilloids
[13,14]. More importantly, TRPV1-mediated currents induced
by capsaicin, endogenous vanilloids and ethanol can be enhanced
by low pH [15]. TRPV1 participates in nociception especially
under acidic conditions [16] and is considered to play an
important role in cancer pain [17]. Clinical investigation found
TRPV1 over-expression in patients with pancreatic carcinoma
[18], bladder cancer [19] and breast cancer [20], and such an
over-expression is positively correlated with the intensity of pain
[18]. Therefore, in the present study, we postulated that excessive
cancer tissue-derived endogenous formaldehyde induces bone
cancer pain via TRPV1 especially under an acidic tumor
microenvironment.
Results
Formaldehyde concentration increased in cultured
cancer cell lines and tumor tissues from cancer patients
We first investigated whether formaldehyde concentration was
elevated in cultured tumor cell lines in vitro. Formaldehyde
concentrations in rat breast cancer cell line MRMT-1 cells were
significantly higher on day 2 than those of controls on the first day
after cell density reached 10
5 cells/ml and 8610
5 cells/ml
respectively, but decreased on day 3 when the cell density
decreased (n=6) (Fig. 1A). Formaldehyde concentration was also
significantly increased in human lung cancer cell line H1299 cells
and SY5Y cells (Fig. 1, B and C). Syngeneic Walker 256
mammary gland carcinoma cells were cultured by seeding into
the abdominal cavity. A significant increase in the formaldehyde
concentration was found in 0.5 ml ascitic fluid (2610
7 cells/ml)
6 d and 12 d after inoculation. Formaldehyde concentration was
elevated two fold on day 6 after inoculation (from 0.04 mM to
0.08 mM) and decreased on day 12 when tumor cells grew into
terminal phase. The highest concentration was 0.10 mM (Fig. 1D).
Formaldehyde concentration was significantly elevated in bone
marrows of MRMT-1 cancer pain model as compared with that in
normal bone marrow (Fig. 1E). These results indicate that the
formaldehyde concentration was elevated in all tested tumor cell
lines.
Pain visual analogue scores (VAS) were used in groups of
patients with (n=19) and without (n=6) breast pain. Nineteen
patients had significantly suffered from cancer pain. Only 1 patient
reported thermal pain descriptors (burning, hot), while most
reported ache and tenderness. VAS scores in these patients and
controls were 3.860.3 and 0.360.2 respectively. Formaldehyde
concentration was examined in tumor tissues from patients
(Fig. 1F). In preparations from lung cancer patients, the average
formaldehyde concentration was 0.7260.06 mM (n=10) with the
highest concentration 1.01 mM. This was significantly higher than
that in the normal tissues adjacent to the cancer (0.1960.06 mM).
In breast cancer tissues from patients, the formaldehyde
concentration was 0.7560.12 mM with the highest concentration
2.35 mM. Although the breast tumor adjacent tissues (as controls)
were not gained, levels of formaldehyde in human tissues were
approximately 0.1,0.2 mM as previously reported [21]. These
levels are similar to the average level (0.1960.06 mM) found in
human lung cancer adjacent tissues in the present experiment.
Taken together, these data show that the tumor-derived
formaldehyde concentration is elevated in cancer tissues, strongly
suggesting that tumor tissues secrete formaldehyde.
Formaldehyde scavengers and TRPV1 antagonists
attenuated formalin-induced pain behaviors
The formalin test (5% formalin, i.e. 1662 mM formaldehyde) is
a classic pain model commonly used to evaluate analgesic
medicines. We found that formaldehyde scavengers glutathione
(GSH) and resveratrol (Res), and TRPV1 antagonists capsazepine
(CPZ) and melatonin (MT) significantly decreased the number of
flinchings in a dose-dependent manner in both acute and tonic
phases (Fig. 2, A–D), similar to that in previous reports [1,22]. The
solvent used for these regents, DMSO (final concentration ,10%)
by itself did not show significant effect (Fig. 2A).
Low concentration formaldehyde-induced pain
behaviors via TRPV1 was enhanced by low pH
Formalin 5% functioning as a chemical irritant can induce
nociceptive behavioral responses (pain). This in turn raises an
interesting question of whether formaldehyde at pathologically low
concentrations (1,3 mM, based on the concentrations of
formaldehyde detected in human tumor tissues) can induce pain
responses, and whether TRPV1 or TRPA1 is involved in the pain
responses. Intraplantar injection of formaldehyde (0.1 mM to
100 mM) to the right hind paw evoked dose-dependent, short-
lasting (5 min) pain responses of the injected paw in normal rats.
Capsazepine, melatonin and AP-18 (a TRPA1 antagonist) all
attenuated the low concentration formaldehyde (5 mM)-induced
pain responses (Fig. 3A). These results indicate that formaldehyde
at low pathological concentration can induce pain behavioral
responses, possibly through activation of TRPV1 and TRPA1.
In addition, formaldehyde (3 mM) with a low pH of 5.0 or 6.0
(mimicking the acidic cancer microenvironment) induced more
severe pain responses than formaldehyde in a neutral environment
(pH 7.4). These responses were partially inhibited by AP-18, but
almost completely inhibited by capsazepine (a TRPV1 antagonist)
(Fig. 3B). Moreover, capsazepine and melatonin attenuated
capsaicin-induced pain responses (Fig. 3C), but AP-18 did not
(Fig. 3D). This result is similar to a previous report [23]. These
data suggest that TRPV1, but not TRPA1, plays a key role in low
concentration formaldehyde-induced pain behaviors under acidic
environment.
Formaldehyde induced Ca
2+ influx in dorsal root
ganglion (DRG) neurons and TRPV1-CHO cells in vitro
We further used calcium imaging to test whether low
concentration formaldehyde can directly excite DRG neurons
via TRPV1. As expected, formaldehyde at concentrations of
1 mM to 100 mM induced a concentration-dependent increase of
[Ca
2+]i in freshly isolated rat DRG neurons (Fig. 4, A and B).
TRPV1 antagonists capsazepine and melatonin inhibited the
[Ca
2+]i increase evoked by formaldehyde (Fig. 4, C and D) or by
capsaicin (Fig. 4, E and F).
To verify whether formaldehyde directly activates TRPV1, we
next examined the effect of formaldehyde on TRPV1-transfected
Formaldehyde and Cancer Pain
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induced an increase of cytosolic [Ca
2+]i in a concentration-
dependent manner (Fig. 4, G and H). As a control, in the
untransfected CHO cells, formaldehyde at 100 mM elicited only
slight Ca
2+ influx (data not shown). Formaldehyde induced Ca
2+
influx in the TRPV1-CHO cells was significantly inhibited by the
TRPV1 antagonist capsazepine and melatonin (Fig. 4, I and J).
Formaldehyde and pH 6.0 synergistically elicited currents
in TRPV1-CHO cells in vitro
Since nociceptive behaviors (pain) induced by formaldehyde at
pH 6.0 were sensitive to the TRPV1 antagonist, formaldehyde at
pH 6.0 may act directly on TRPV1 (Fig. 3B). We recorded the
TRPV1 current induced by capsaicin and formaldehyde (with or
without pH 6.0) using patch clamp recording in TRPV1-CHO
cells. Capsaicin at 10 mM induced an inward current with voltage
clamped at 260 mV. Capsazepine, a TRPV1 antagonist, strongly
suppressed the capsaicin-induced current. Similarly, formaldehyde
at 3 mM (concentration detected in human tumor tissues) induced
an inward current in TRPV1-CHO cells in a concentration-
dependent manner and 10 mM capsazepine blocked the formal-
dehyde-induced current (Fig. 5A). As controls, neither 3 mM
formaldehyde, nor 10 mM capsaicin, nor formaldehyde plus
capsaicin induced any current in the untransfected CHO cells
(data not shown).
Although low pH of 6.0 in extracellular solution had little effect
on TRPV1-CHO cells, currents induced by formaldehyde at
1,10 mM were significantly potentiated by pH 6.0 (Fig. 5, A and
B). This result indicates that there is a synergistic effect between
formaldehyde and an acidic environment. As a positive control,
formaldehyde at 1 and 3 mM also markedly potentiated capsaicin
(1 mM)-induced current in the TRPV1-CHO cells (Fig. 5, C and
D). These data suggest that formaldehyde directly activates
TRPV1 with more efficiency at low pH.
Formaldehyde and pH 5.0 synergistically elicited C-fiber
discharges via TRPV1 in vivo
Of greater importance, we tried to determine whether formal-
dehydewithinthe concentrationrange detectedinthecancertissues
from patients is functional in exciting peripheral nociceptive nerve
fibers. Peripheral C-fibers transduce nociceptive information to
conduct nociceptive information. An increase in nociceptive C-fiber
firings is a common characteristic of pain. Since formaldehyde at
pH 5.0 (mimicking an extremely acidic tumor microenvironment)
induced more severe pain behaviors than pH 5.0alone (Fig. 3B), we
tested whether formaldehyde can excite C-fibers. It was found that
formaldehyde (1 mM, similar to the levels detected in human lung
cancer tissues)at pH 5.0candirectly exciteC-fibers.Thenumberof
action potentials increased significantly after formaldehyde (under
pH 5.0)injectionintothereceptivefieldoftheC-fibers.ThisC-fiber
excitation could be blocked by the TRPV1 antagonist capsazepine
(CPZ) (Fig. 5, E and F).
Formaldehyde scavengers inhibited formaldehyde-
induced neurotoxicity in cultured DRG neurons
We further tested the neurotoxicity of formaldehyde within the
above-measured concentration range (.0.1 mM) in the cultured
DRG neurons. It was shown that formaldehyde was neurotoxic to
DRG neurons in a dose-dependent manner (Fig. 6A). Resveratrol,
an exogenous formaldehyde scavenger, and glutathione, an
endogenous formaldehyde scavenger, showed spontaneous chem-
ical interaction with formaldehyde in PBS solution within 40
minutes (Fig. 6B). These formaldehyde scavengers decreased
formaldehyde-induced neurotoxicity with a concentration-depen-
dent manner (Fig. 6, C and D).
Formaldehyde scavengers and TRPV1 antagonists
attenuated bone cancer pain behaviors in rats
As shown in Fig. 7A, X-ray revealed that no radiological change
(score =0) was found in animals treated with heat-killed tumor
cells or with PBS solution. However, 7 days after injection with
MRMT-1 cells, the bone showed some loss of medullary bone and
apparent erosion of the cortical bone. Further deterioration was
detected on day 15 post-injection with additional full thickness
unicortical bone loss. Formaldehyde scavengers (glutathione and
resveratrol) and melatonin all significantly decreased bone
destruction; however, capsazepine, a TRPV1 antagonist, did not
protect bone structure from erosion on day 15 (Fig. 7, A and B).
Pain behaviors including thermal hyperalgesia and mechanical
allodynia were observed from 7 to 15 days after injection of
MRMT-1 cancer cells. It was also found that the pain behaviors
were attenuated by capsazepine, melatonin and formaldehyde
scavengers (glutathione and resveratrol) on days 11 and 15 after
MRMT-1 inoculation (Fig. 7, C and D).
It was of interest to note that even though capsazepine and
melatonin both attenuated bone cancer pain behaviors, the
formaldehyde concentration in the spinal cord and blood of the
cancer pain model rats on days 15 was still kept higher than that of
the control rats. More importantly, resveratrol and glutathione
(formaldehyde scavengers) inhibited bone cancer pain behaviors
by decreasing excessive formaldehyde in the spinal cord (Fig. S1,
A and B).
Discussion
Tumor tissues directly secrete endogenous
formaldehyde
The physiological formaldehyde level was reported to be
approximately 0.1 mM in the blood or brain of human and
non-human animal [21]. Surprisingly, clinical data showed that
formaldehyde concentrations were significantly elevated (2,8 fold)
in urine from patients with bladder cancer and prostate cancer [3],
in the expiration of some patients suffering from breast cancer [4]
and especially high in blood samples (8,10 folds) from certain
patients with tumor [24]. Formaldehyde was also elevated in
lymphocytes in chronic lymphocytic leukemia [7]. The expression
and activity of formaldehyde generating enzymes, such as lysine-
specific demethylase 1 (LSD1) [25,26], semicarbazide-sensitive
amine oxidase (SSAO) [27,28] and cytochrome P-450 [29,30],
formaldehyde degrading enzymes, such as aldehyde dehydroge-
nase 2 (ALDH2) and class III alcohol dehydrogenase (ADH3)
[31,32], are considered to have critical roles in the pathogenesis of
breast cancer. Over-expression of ADH3 has been found in cancer
tissues, which defenses formaldehyde [33]. This implies that tumor
tissues can tolerate formaldehyde at abnormal levels. The present
Figure 1. Formaldehyde concentration in the cultured cancer cell lines in vitro and in vivo. (A) MRMT-1 cancer cells. (B) Human H1299 lung
cancer cells. (C) Human SY5Y cancer cells. (D) Ascites from peritoneal inoculation of Walker 256 mammary gland carcinoma cells. (E) Bone morrow of
MRMT-1 breast cancer pain model rat in vivo. (F) Tumor tissues from lung and beast cancer patients. * p,0.05,
** p,0.01, compared with that of the
first day.
doi:10.1371/journal.pone.0010234.g001
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from the cultured cancer cell lines in vitro and tumor tissues from
certain cancer pain patients in vivo, and its concentration may
reach abnormally high levels (Fig. 1). Because the bone cavity
volume of rats is small and the amount of bone marrow tissue is
little, four bone marrows from MRMT-1 breast cancer pain
models were combined to one tube for HPLC measurement in the
present study. A marked elevation of formaldehyde level was
found in bone marrow of cancer pain model rats (Fig. 1E). This
agrees with a previous report that formaldehyde could be
accumulated in bone marrow [34]. Interestingly, formaldehyde
level in blood was also obviously elevated in MRMT cancer pain
model in rats (Fig. S1, B) and formaldehyde is considered as a
cause of cancer [35]. These reports suggest that excessive
formaldehyde production by tumor tissues is possibly a critical
factor in tissue cancerization or osseous metastasis.
Cancer tissue-derived excessive formaldehyde induces
bone destruction
Cancer cell metastasis to bone marrow increases osteolysis,
osteoclastic activity and induces an acidic microenvironment [36].
This is related to the fact that osteoclasts resorb bone by
maintaining an extracellular microenvironment of pH 4,5 [12].
Acidification is a cause of pain in cancer and inflammation [36].
The activated osteoclasts increase proton-induced stimulation of
TRPV1 or acid-sensitive ion channels (ASICs) on sensory nerve
Figure 2. TRPV1 antagonists and formaldehyde scavengers inhibited formalin-induced pain response in rats. (A) Capsazepine (CPZ, a
TRPV1 antagonist); (B) Melatonin (MT); (C and D) Formaldehyde scavengers: Resveratrol (Res) and Glutathione (GSH). mg/paw. * p,0.05,
** p,0.01,
compared with the formaldehyde injection groups. n=10.
doi:10.1371/journal.pone.0010234.g002
Formaldehyde and Cancer Pain
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tumor cells themselves. Cancer cells have a lower intracellular pH
than normal cells [37], as solid tumors outgrow their vascular
supply, then cancer tissue becomes necrotic, which contributes to
the acidic environment [38]. A recent research report also
demonstrated that formaldehyde, gradually released by root canal
sealers, elicited bone necrosis [39]. Elevated formaldehyde was
also observed in patients with dental caries [40]. Cytotoxicity
resulting from excessive formaldehyde on human osteoblastic cells
has been considered to be an important factor in bone destruction
[41,42]. Formaldehyde can accumulate in bone marrow [34]. In
our present study, formaldehyde concentration was elevated to
about 0.6 mM in bone marrow of MRMT-1 bone cancer pain
model in rats (Fig. 1E). This level is high enough to be toxic to
osteoblastic cells. Bone destruction was found in the MRMT-1
bone cancer pain model in rats. Formaldehyde scavengers,
resveratrol and glutathione obviously decreased bone destruction
in the present study (Figs. 6B, 7A and 7B). Therefore, excessive
formaldehyde secreted by cancer tissues may play a role in bone
destruction. This bone destruction then contributes to cancer pain,
because nerve fiber endings innervating bone is more easily
exposed to tumor tissue-derived factors.
Formaldehyde induces pain responses via TRPV1 and/or
TRPA1
Breast, lung and bladder cancer patients frequently suffer from
bone cancer pain [5,6]. In the present study, mechanical allodynia
was found in breast cancer pain patients and in the affected hind
Figure 3. Capsaicin- or formaldehyde (100 ml/paw)-induced acute pain responses. (A) Melatonin, capsazepine and AP-18 attenuated
formaldehyde-induced pain responses. (B) Low pH enhanced formaldehyde-induced pain responses. (C) Melatonin (MT) and capsazepine (CPZ)
blocked capsaicin (0.5 mM)-induced pain responses. (D) AP-18 did not block capsaicin-induced pain responses. Con: control; DMSO: vehicle; CAP:
capsaicine. * p,0.05, ** p,0.01,
## p,0.01,
& p,0.05,
&& p,0.01, all compared with respective controls. n=10.
doi:10.1371/journal.pone.0010234.g003
Formaldehyde and Cancer Pain
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C); this result is similar to that observed in a previous report [43].
The MRMT-1 bone cancer pain model is widely used in breast
cancer bone pain research [44]. TRPV1 antagonists attenuated
endogenous formaldehyde-induced bone cancer pain behaviors
(Fig. 7, B and C). The selective TRPV1 antagonists, such as iodo-
resiniferatoxin [45] and capsazepine, and the non-selective
antagonist ruthenium red [46], inhibited formalin-induced pain
behaviors. These findings suggest that TRPV1 may participate in
formaldehyde-evoked pain. In our behavior tests, we found that
formaldehyde at low pathological (3 mM, based on concentration
detected in human cancer tissues) in an acidic environment
induced rat pain responses via TRPV1 in vivo (Fig. 3B).
Capsazepine (a TRPV1 antagonist) attenuated capsaicin- or
formaldehyde- (pH 6.0) induced pain responses in rats (Fig. 3,
B–D). A recent study also showed that TRPV1 participates in
nociception especially under extremely acidic conditions [16].
Recent researches have shown that both TRPA1 and TRPV1
are possible targets of endogenous formaldehyde in vitro and in vivo
[9]. In the report of Macpherson et al, formaldehyde-evoked
calcium responses in DRG neurons and nocifensive behaviors
were almost abolished in TRPA1
2/2 mice. At the same time,
formaldehyde could still evoke pain responses in the TRPA1
2/2
mice. This suggests that formaldehyde does not merely activate
TRPA1. In our present study, formaldehyde (.0.1 mM) was
found to activate TRPV1 (Fig. 1A), especially in the acidic
environment. We think that TRPV1 or TRPA1 are all under the
mechanisms of pain. AP-18 (a TRPA1 antagonist) partially
decreased formaldehyde-induced pain (pH 5.0,6.0) and did not
attenuated capsaicin-induced pain behaviors (Fig. 3B). This
implies that under an acidic microenvironment of cancer tissues,
TRPV1 may play a more critical role than TRPA1. Whether
TRPA1 also participates in bone cancer pain is unknown, but will
be investigated in our further research.
Formaldehyde under acidic environment induces pain
responses via TRPV1
With patch clamp recording, it was found that formaldehyde
(.3 mM) activated TRPV1 directly in TRPV1-transfected CHO
cells. While neither an acidic environment alone (pH 6.0), nor
formaldehyde at low concentration alone (,3 mM) elicited
currents, formaldehyde at the same low concentration under an
acidic environment (pH 6.0) dose-dependently induced currents
via TRPV1 (Fig. 5, A and B). In fact, formaldehyde (1,10 mM)
did not elicit currents in ASIC1a-transfected CHO cells (data not
shown). These data indicate that TRPV1 (and not ASIC1a) is the
direct target of formaldehyde, especially formaldehyde in an acidic
environment. Formaldehyde also enhanced capsaicin-induced
currents in vitro (Fig. 5, C and D). Formaldehyde level was
elevated to about 0.6 mM in the bone morrow of this model in vivo
(Fig. 1E), and formaldehyde (1 mM) under an acidic environment
(pH 5.0) elicited C-fiber discharges in vivo (Fig. 5, E and F).
Formaldehyde-induced pain responses in rat were obviously
enhanced under an acidic environment (pH 5.0) in vivo (Fig. 3, A
and B). It has been reported that microenvironment of tumor
tissues has pH values of 4,5 [12], and that pain behaviors could
be induced at a pH as low as 5.0 through activation of ASICs and/
or TRPV1 [15]. These data suggests that accumulated formalde-
hyde and acidic environment in tumor tissues synergistically
induce pain responses by activating TRPV1 in afferent C-fiber of
bone marrow or skin.
Moreover, formaldehyde up-regulated NGF expression in mast
cells in vitro, and NGF secreted by mast cells and macrophages could
up-regulate TRPV1 [2]. Thisimplies that formaldehydesecreted by
tumor tissues possibly up-regulates TRPV1 expression. Interesting-
ly, over-expression of TRPV1 has been found in bone morrow,
DRG neurons and afferent C-fibers in bone cancer pain models
[1,47]. Therefore, we hypothesize that the proliferating cancer cells
secrete excessive endogenous formaldehyde in the initial stages, and
then formaldehyde up-regulates TRPV1 expression in the afferent
nerves. Consequently, over-expression of TRPV1 increases me-
chanical sensitization by decreasing pain thresholds of patients with
cancer. Then, as the tumor progresses, acceleration of acidification
and chronic accumulation of formaldehyde lead to mechanical
allodynia or severe pain via ASICs and/or TRPV1 in skin or bone
marrow of the cancer patients (Fig. S2).
Although, blockade of TRPV1 has been suggested as a possible
therapeutic target to relieve pain [1], recent research has shown
that the chronic blockade of this receptor may increase risk of
cancer development [48]. In our study, we found that although
capsazepine and melatonin all attenuated bone cancer pain
responses, they did not decrease local formaldehyde levels in
spinal cord and blood (Fig. S1, A and B). More importantly,
formaldehyde can promote proliferation of cells [49], and it is a
risk factor for cancer development [7]. This hints that formalde-
hyde may be a critical factor of the glial over-proliferation in the
spinal cord of this bone cancer pain model [44]. Interestingly,
melatonin has been used clinically for breast cancer [50]. We
found that it inhibited acute formaldehyde- and capsaicin-induced
pain behaviors (Fig. 3, A and C), as shown previously [22,51–52];
and it blocked formaldehyde or capsaicin-elicited Ca
2+ influx in
DRG neurons and TRPV1-transfected CHO cells (Fig. 4). But,
the melatonin receptor is not expressed in DRG neurons and
CHO cells [53,54]. Melatonin may act by antagonizing TRPV1.
Potential side effects of chronic blockade of TRPV1 require
further investigation.
Formaldehyde scavengers decrease pain responses by
decreasing formaldehyde level
In the classical formalin test, resveratrol (exogenous formalde-
hyde scavenger) [55,56] and glutathione (endogenous formalde-
hyde scavenger) [57–59] inhibited formalin-induced pain respons-
es (Fig. 3, C and D). To test whether resveratrol and glutathione
are formaldehyde scavengers, at the molecular level, we found that
resveratrol and glutathione brought about chemical deactivation
of formaldehyde in vitro (Fig. 6B). At the cellular level, they also
inhibited formaldehyde-induced neurotoxicity (Fig. 6, C and D); at
the tissues level, resveratrol and glutathione attenuated MRMT-1
bone cancer pain responses in rats by decreasing endogenous
formaldehyde levels in the spinal cord in vivo (Fig. S1A). These
data further confirm that they are formaldehyde scavengers.
Resveratrol inhibits proliferation of cancer cell by scavenging
Figure 4. Formaldehyde-induced increase in cytosolic [Ca
2+]i in cultured DRG neurons and in TRPV1-CHO cells. (A) Formaldehyde-
induced dose-dependent increase of cytosolic [Ca
2+]i in DRG neurons. (B) Statistical analysis of formaldehyde-induced [Ca
2+]i influx in DRG neurons.
(C and D) Inhibition of capsazepin (CPZ, 100 mM) and melatonin (MT, 200 mM) on formaldehyde-induced [Ca
2+]i influx in DRG neurons. (E and F)
Inhibition of MT and CPZ on capsaicin (CAP, 10 mM)-induced Ca
2+ influx in DRG neurons. (G) Formaldehyde-induced dose-dependent increase of
cytosolic [Ca
2+]i in TRPV1-CHO cells. (H) Statistical analysis of formaldehyde-induced Ca
2+ influx in TRPV1-CHO cells. (I and J) Inhibition of MT and CPZ
on formaldehyde-induced Ca
2+ influx in TRPV1-CHO cells.
** p,0.01, compared with controls. n=5,10.
doi:10.1371/journal.pone.0010234.g004
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PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10234Figure 5. Enhancement of low pH on formaldehyde- or capsaicin-induced TRPV1 currents in TRPV1-CHO cells in vitro and
formaldehyde-induced C-fiber discharges in vivo. (A) Formaldehyde (FA)-induced currents and pH 6.0 enhancement on the currents with
patch clamp recording. TRPV1 antagonist capsazapine (CPZ) inhibited both the formaldehyde-induced currents and the pH 6.0 enhancement. (B)
Statistical results of low pH enhancement of formaldehyde-induced currents. (C) Formaldehyde enhancement on capsaicin (CAP)-induced currents.
(D) Statistical results of formaldehyde enhancement on capsaicin-induced currents. n=6,10. (E) Formaldehyde-induced C-fiber discharges under an
acidic environment (pH 5.0) with extracellular recording in normal rats. The discharge was inhibited by CPZ. (F) Statistical results of CPZ inhibition on
the formaldehyde-induced C-fiber discharges. * p,0.05, ** p,0.01. n=3.
doi:10.1371/journal.pone.0010234.g005
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mechanism by which resveratrol defends against all kinds of
cancer [61]. A previous study showed that the level of glutathione
was significantly decreased in the blood of patients with breast
cancer [62]. Moreover, by conferring resistance to a number of
chemotherapeutic drugs, elevated levels of glutathione in tumor
cells are able to protect these cells in bone marrow, breast, colon,
larynx and lung cancers [63]. Both resveratrol and glutathione
compounds are antioxidants. Interestingly both TRPA1 and
TRPV1 are activated by oxidative stress [64,65]. The antioxidant
effect of resveratrol and glutathione may partially prevent
oxidative stress-induced pain.
In summary, the present study indicates that accelerated
acidification and chronically accumulated formaldehyde which
are derived from local cancer tissues synergistically stimulate nerve
fiber endings and lead to bone cancer pain. Use of formaldehyde
scavengers may be a novel therapeutic approach for treatment of
bone cancer pain.
Materials and Methods
Ethics statement
All experiments involving animals were conducted with the
approval of the Peking University Animal Care and Use
Committee. Informed consent was obtained for all participants
and written by themselves. All the clinical investigation was
performed after approval by the Ethics Committee of Peking
University Health Science Center.
Cancer tissues from patients suffered from bone cancer
pain after clinic pain assessment
In all cases, bone cancer pain was indicated based upon clinical
diagnosis. A questionnaire which included a diagram to indicate
painful and tender areas and the pain descriptors from the McGill
Pain Questionnaire were produced, along with a 10-cm unmarked
visual analogue scale (VAS), and VAS scores marked by the
patient in centimeters being more than zero to identify those
Figure 6. Inhibition of formaldehyde scavengers on formaldehyde-induced neurotoxicity. (A) Formaldehyde (FA) decreased cell viability
of the cultured DRG neurons with a dose-dependent manner. (B) Chemical reaction of formaldehyde with resveratrol and glutathione. (C) Resveratrol
(Res) and (D) glutathione (GSH) inhibition on the formaldehyde-induced cell viability decrease. * p,0.05, ** p,0.01,
# p,0.05,
## p,0.01. n=6.
doi:10.1371/journal.pone.0010234.g006
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patients and 6 normal women carried out the clinical pain
assessment by doctors. Tumor samples from 19 breast cancer
patients and clinic data were provided by the Department of
General Surgery, Peking University Third Hospital. Tissues
adjacent to breast cancer were adipose tissue and were not used
in this study. Tumor samples from 10 lung cancer patients which
included adenocarcinoma, squamous cell carcinoma and pulmo-
nary lymphoma were provided by the Department of Thoracic
Surgery, Peking University People’s Hospital, tissues adjacent to
cancer were obtained from 4 lung cancer patients. Both cancer
tissues and tissues adjacent to cancer were frozen immediately with
and stored in liquid nitrogen until they were used for evaluation of
formaldehyde concentration.
Bone cancer pain rat model
A rat bone cancer pain model was established using Sprague-
Dawley rats with MRMT-1 rat mammary gland carcinoma in a
manner similar to that in a previous report [67]. After anesthesia,
the tibia was carefully exposed and a 23-gauge needle was inserted
into the intramedullary canal of the bone. It was then removed
and replaced with a long thin blunt needle attached to a 10-ml
Hamilton syringe containing carcinoma cells. A volume of 4 ml
containing MRMT-1 cancer cells (4610
4), heat-killed cancer cells
Figure 7. Inhibition of TRPV1 antagonists or formaldehyde scavengers on rat MRMT-1 bone cancer pain behaviors. (A) Radiological
confirmation of tumor development in the tibia of MRMT-1 pain model rats. (B) Scores related to the tibia (bone) in different treatment groups. n=4.
(C) Thermal hyperalgesia. Formaldehyde scavengers resveratrol (Res, 0.4 mg/ml) and glutathione (GSH, 25 mg/ml), TRPV1 antagonists capsazepine
(CPZ, 0.1 mg/ml) and melatonin (MT, 5 mg/ml) increased hot plate latency. (D) Mechanical allodynia. Res, GSH, CPZ and MT increased mechanical
threshold. * p,0.05, ** p,0.01;
# p,0.05,
## p,0.01,
$ p,0.05, compared with respective PBS groups. n=10. Killed: heat-killed group.
doi:10.1371/journal.pone.0010234.g007
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cavity. Following injection, the entry site on the bone was sealed
with bone wax. Doses of test reagents were given at 9, 11, 13 and
15 day respectively, including capsazepine (intravenous injection
through the tail or intraperitoneal injection, i.p.) and resveratrol
(i.p.). These regents were dissolved in DMSO (final concentration
,10%). Glutathione (i.p.) was dissolved in normal saline. All
reagents were obtained from Sigma, unless otherwise indicated.
The bone marrow and spinal cords of these rats were taken out for
formaldehyde measurement with HPLC.
To assess the bone destruction after inoculation, tibial bone
radiographs from both hind limbs on 7 and 15 days were taken
with a Digital Radiographer System (E-COM Technology Co.
Ltd., Guangdong, China). Radiological scores were given based on
careful, blind analysis of radiographs, taken from the ipsilateral
and contralateral legs of MRMT-1-treated, heat-killed MRMT-1-
treated, vehicle-treated and naive rats (n=4 for each group).
Scores were given as in previous report [44]. All scores related to
the tibia (bone): 0, normal bone structure without any sign of
deterioration; 1, small radiolucent lesions in the proximal
epiphysis, close to the site of the injection; 2, increased number
of radiolucent lesions, loss of medullary bone; 3, loss of medullary
bone, plus erosion of the cortical bone; 4, full thickness unicortical
bone loss; 5, full thickness bicortical bone loss and displaced
fractures.
Hot plate test for thermal hyperalgesia
Male Sprague-Dawley rats (150,200 g) were provided by the
Department of Animal Science of Peking University. Animals were
raised under natural diurnal cycles and had free access to water
and food. They were habituated to the testing paradigms for 3,5
days before experiment. Animal treatment was in compliance with
the Guidelines of the International Association for the Study of
Pain [68]. On days 1, 3, 7, 11 and 15 after injection of MRMT-1
cells, heat-killed cells or PBS injection, thermal hyperalgesia was
tested with hot plate. Rats were habituated to the experimental
environment for 30 min in their home cage. Rats were placed on
the hot plate (5260.5uC) and the interval time until the rat jumped
or licked either of its hind paws was recorded as hot plate latency.
Following a response, the rat was immediately removed from the
plate. Each test was repeated three times with a 15 min interval
between tests [69].
Von Frey hair test for mechanical allodynia
Each animal was placed in a clear Plexiglas compartment with a
mesh floor and was allowed to habituate for 20 min. On days 1, 3,
7, 11 and 15 after injection of MRMT-1 cells, heat-killed cells or
PBS, mechanical allodynia was evaluated with application of von
Frey hair (Semmes-Weinstein Monofilaments, North Coast Medial
Inc., San Jose, CA) in ascending order of force (0.41,15.1 g) to
the plantar surface of the hind paw. The rat was placed in the test
box and allowed to settle in for 5,10 min. An ascending series of
von Frey hairs with logarithmically incremental stiffness (0.40, 0.60,
1.4, 2.0, 4.0, 6.0, 8.0, and 15.0 g) were applied perpendicular to
the mid-plantar surface (avoiding the less sensitive tori) of each
hind paw. Each von Frey hair was held about 1,2 s, with a 10-min
interval between each application. A trial began with the
application of the 2.0 g von Frey hair. The positive response was
defined as a withdrawal of hind paw upon the stimulus. Whenever
a positive response to a stimulus occurred, the next lower von Frey
hair was applied, and whenever a negative response occurred, the
next higher hair was applied. The testing consisted of five more
stimuli after the first change in response occurred, and the pattern
of response was converted to a 50% von Frey threshold using the
method as previously reported [70].
Classic formalin-induced spontaneous pain (formalin
test)
Following a 30-min habituation to the observation cage, male
Sprague-Dawley rats (300,350 g) received an s.c. injection of
50 ml of a 5% formalin (1662 mM formaldehyde) solution into the
dorsal aspect of the right hind paw. Nociceptive behaviors which
were recorded included flinching, licking or biting the injected paw
as previously described [22,51]. Test reagents with or without
formalin was injected into paw plantar aspect of the paw.
Capsazepine, melatonin, AP-18 and resveratrol were dissolved in
DMSO (final concentration ,10%); formalin and glutathione
were dissolved in normal saline.
Formaldehyde test for acute nociception
Following a 20 min adaptation, rats received a subcutaneous
injection of formaldehyde (0.1,100 mM) at pH 5.0 or 6.0
(mimicking a moderate to severely acidic tumor microenviron-
ment) into the plantar of right hind paw using a microsyringe with
a 26-gauge needle. The length of time that the animals spent
flinching, lifting, licking or biting the injected paw was recorded
with a chronometer, and was considered as an indicator of pain
response in the early phase (0,5 min) as previously described
[46]. Agonists or antagonists (100 ml/paw) which were injected
included capsazepine, AP-18 and melatonin which were dissolved
in DMSO (final concentration ,10%). Formaldehyde was
dissolved in normal saline.
Cell culture
Chinese hamster ovary (CHO) cells were cultured in Ham’s F-
12 medium. MRMT-1 rat mammary gland carcinoma cells
(Novartis Oncology Research, Basel) and H1299 human lung
cancer cells were cultured in RPMI 1640 (Gibco) medium, human
SY5Y cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM). All culture dishes were kept in an incubator
under a humidified atmosphere (37uC, 95% air and 5% CO2).
Dorsal root ganglion (DRG) neuron culture was carried out
following a modification of a previously described procedure [71].
Briefly, DRG from 3-week-old SD rats were digested with trypsin/
EDTA solution for 40 min and dissociated in growth medium
containing DMEM, 5% inactivated fetal bovine serum, 5 mM
glutamine, B27 supplement (GIBCO), 100 ng/ml of nerve growth
factor (Becton Dickinson) and 0.6% dextrose. Cells were seeded at
a density of 5610
5 per well. After 2 days, cultures were treated
with 10 mM cytosine arabinoside to control growth of dividing
cells. Cells were used one week after culture.
Cell viability assayed with MTT
MTT solution was prepared in complete medium to a
concentration of 1 mg/ml just before use. Cells were diluted in
fresh complete medium and seeded in 96-well plates. After
allowing overnight attachment, cells were treated with various
concentrations of formaldehyde or reagents for 4 h. Optical
density were determined by a spectrophotometer.
Formaldehyde measurement with high performance
liquid chromatography with fluorescence detection
(Fluo-HPLC)
Media from the cultured cancer cell lines, bone marrows, the
homogenate of spinal cords of model rats and cancer patient tissue
specimens were harvested for formaldehyde assay. An HP 1100
Formaldehyde and Cancer Pain
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was used. The method was as described in our previous report [72].
Cytosolic Ca
2+ concentration in TRPV1-transfected CHO
cells and DRG neurons
For transfection of CHO cells with TRPV1 plasmids, CHO
cells were harvested after brief trypsin digestion and seeded onto
confocal plate chambered cover-glasses (LabTek, Nunc) precoated
with 20 mg/ml poly-L-lysine. Actively growing cells were trans-
fected with a pcDNA3.1-TRPV1 plasmid by lipofectamine plus
(Life Technologies, Rockville, MD, USA). Control cells were
transfected with pcDNA3.1 plasmid only. After 16,24 h culture,
cells were challenged with formaldehyde or capsaicin. DRG
neurons were freshly isolated with trypsin and collegenase
digestion as in our previous report [73].
TRPV1-CHO cells and DRG neurons were loaded with 50 mM
Fluo-3/AM (Molecular Probes) and incubated for 30 min at 37uC.
Fluo-3/AM was excited at 488 nm, and its emitted fluorescence
was collected at 515 nm. The control bath solution (pH 7.4) was
used as described previously [69]. Changes in cytosolic [Ca
2+]i
concentration in the TRPV1-CHO cells and in the DRG neurons
were measured with a confocal laser scanning microscope (Leica
Company Ltd., Germany).
Whole cell patch-clamp recording of TRPV1 current in
vitro
Recordings in TRPV1-CHO cells were made with standard
whole-cell patch-clamp method as described in our previous
report [73]. Experiments were carried out at room temperature
(22,24uC). The extracellular solution consisted of 130 mM NaCl,
5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 30 mM glucose and
25 mM HEPES-NaOH and the pH was adjusted to 7.3. Patch
pipettes(resistance2,5M V) werefilledwith 140 mMCsCl, 4 mM
MgCl2, 10 mM EGTA and 10 mM HEPES-CsOH (pH 7.3).
Reagents were applied with an automated perfusion device.
Extracellular electrophysiological recording of C-fiber
firing in vivo
Male Sprague-Dawley rats weighing 300,350 g were anesthe-
tized with urethane (1.5 g/kg, i.p.). Animal preparation and the
teased fiber recording method were carried out as previously
reported [73]. Briefly, the L5 dorsal root was exposed by lumbar
laminectomy and covered with warmed (36uC) paraffin oil. Fine
axon bundles (microfilaments), cut centrally but in continuity with
the DRG distally, were separated from the dorsal root near its
point of entry into the spinal cord. C-fiber was recorded for 2 min
to detect its receptive field and to confirm its conduction velocity
(less than 2.0 m/s). C-fiber firing within the following 5 min was
taken as the basal firing. After injection of 1 mM formaldehyde
with pH 5.0 (mimicking an extremely acidic tumor microenvi-
ronment) or vehicle only (normal saline, pH 5.0) into the receptive
field of a C-fiber, firing was recorded for another 5 min. The
frequency of the C-fiber firing before and after formaldehyde
injection was compared.
Data analysis
Data are expressed as mean 6 S.E.M. Data from in vitro
experiments were analyzed using the Student’s t test for
comparison of independent means. In vivo data were analyzed by
analysis of variance (ANOVA) followed by Dunnett’s post hoc test
repeated measures of ANOVA, and post hoc tests including
Student’s t test (ex vivo test). p values less than 0.05 were
considered statistically significant.
Supporting Information
Figure S1 Formaldehyde concentration in bone cancer pain
model rats in (A) spinal cord and (B) blood. In MRMT-1 pain
model of rats, formaldehyde (FA) concentration increased. TRPV1
antagonists capsazepine (CPZ 0.1 mg/ml) and melatonin (MT,
5 mg/ml) had no obvious influence on formaldehyde concentra-
tion, but formaldehyde scavengers resveratrol (Res, 0.4 mg/ml)
and glutathione (GSH, 25 mg/ml) decreased FA concentration. *
p,0.05, ** p,0.01; # p,0.05, ## p,0.01, all compared with
PBS groups. n=10.
Found at: doi:10.1371/journal.pone.0010234.s001 (0.33 MB
TIF)
Figure S2 A putative scheme that excessive formaldehyde
secreted by tumor tissues and its induction on bone cancer pain
under an acidic microenvironment.
Found at: doi:10.1371/journal.pone.0010234.s002 (4.24 MB
TIF)
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